Related Experiment Video
Updated: Nov 10, 2025
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
[The Prognostic Factors for AML Children with CBFβ/MYH11 Positive]
Min Yan1, Fu-Xing Song2, Jun Lu3
1Department of Pediatrics Jinan City People's Hospital, Jinan 271199, Shandong Province, China,E-mail: chizunv05@163.com.
Insights
Prognostic factors for pediatric acute myeloid leukemia (AML) with CBFβ/MYH11 rearrangement were analyzed. Lower white blood cell (WBC) counts and specific XRCC genotypes significantly improve outcomes in these AML children.
Area of Science:
- Pediatric Oncology
- Hematologic Malignancies
- Molecular Diagnostics
Background:
- Acute myeloid leukemia (AML) in children with the CBFβ/MYH11 fusion gene presents unique prognostic considerations.
- Identifying key factors influencing treatment outcomes is crucial for improving survival rates in this pediatric subpopulation.
Purpose of the Study:
- To investigate the prognostic significance of clinical and genetic factors in pediatric AML patients with CBFβ/MYH11 rearrangement.
- To determine the impact of white blood cell (WBC) count and XRCC-Thr241Met genotype on overall survival (OS) and event-free survival (EFS).
Main Methods:
- Retrospective analysis of clinical data from 28 pediatric AML patients with CBFβ/MYH11 rearrangement.
- Evaluation of overall survival (OS) and event-free survival (EFS) rates.
- Statistical analysis including univariate and Cox multivariate survival analyses.
Main Results:
- Five-year OS and EFS rates were 76.8% and 64.0%, respectively.
- Lower initial WBC counts (<60.0×10^9/L) were associated with significantly higher OS and EFS rates.
- Wild-type XRCC-Thr241Met genotype showed significantly better EFS compared to variant genotypes.
Conclusions:
- Initial WBC level is a significant risk factor for OS in pediatric AML with CBFβ/MYH11.
- Both initial WBC level and XRCC-Thr241Met genotype are critical prognostic factors for EFS in this patient group.
Objective:
To analyze the prognostic factors of AML children with CBFβ/MYH11 positive.
Methods:
Twenty-eight children with CBFβ/MYH11 positive treated in our hospital from May 2012 to June 2018 were selected, the clinical data and curative were analyzed and evaluated.
Results:
Five-year OS and 5-year EFS rate of CBFβ/MYH11 positive AML children was 76.8% and 64.0% efficacy, respectively. Univariate analysis results showed that the OS rate of CBFβ/MYH11 positive AML children with WBC<60.0×109/L was 86.5%, which was significantly higher than those of CBFβ/MYH11 positive AML children with WBC≥60.0×109/L (χ2=3.891, P<0.05). The EFS rate of CBFβ/MYH11 positive AML children with WBC<60.0×109/L was 76.0%, which was significantly higher than those of AML children with WBC≥60.0×109/L (χ2=4.588, P<0.05). The EFS rate of CBFβ/MYH11 positive AML children with XRCC-Thr241Met wild type was 77.9%, which was significantly higher than those of AML children with XRCC-Thr241Met variant (χ2=3.960, P<0.05). Cox multivariate survival analysis results showed that WBC level at initial diagnosis was the risk factor for OS rate. The WBC level and XRCC-Thr241Met type at initial diagnosis were the risk factors for EFS rate.
Conclusion:
WBC level and XRCC-Thr241Met genotype at initial diagnosis are the major affecting factors for prognosis of AML children with CBFβ/MYH11 positive.
